BE2014C027I2 - - Google Patents
Download PDFInfo
- Publication number
- BE2014C027I2 BE2014C027I2 BE2014C027C BE2014C027C BE2014C027I2 BE 2014C027 I2 BE2014C027 I2 BE 2014C027I2 BE 2014C027 C BE2014C027 C BE 2014C027C BE 2014C027 C BE2014C027 C BE 2014C027C BE 2014C027 I2 BE2014C027 I2 BE 2014C027I2
- Authority
- BE
- Belgium
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/048—Pyridine radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/056—Triazole or tetrazole radicals
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Ophthalmology & Optometry (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US49153403P | 2003-08-01 | 2003-08-01 | |
| PCT/JP2004/011312 WO2005012326A1 (en) | 2003-08-01 | 2004-07-30 | Novel compounds having inhibitory activity against sodium-dependant transporter |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BE2014C027I2 true BE2014C027I2 (US07576130-20090818-C00078.png) | 2023-12-14 |
Family
ID=34115515
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BE2014C027C BE2014C027I2 (US07576130-20090818-C00078.png) | 2003-08-01 | 2014-04-29 |
Country Status (37)
Families Citing this family (199)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1020944C (zh) * | 1990-01-30 | 1993-05-26 | 阿图尔-费希尔股份公司费希尔厂 | 紧固件 |
| KR101001850B1 (ko) | 2003-03-14 | 2010-12-17 | 고토부키 세이야쿠 가부시키가이샤 | Ｃ-글리코시드 유도체 또는 이의 염, 및 이를 포함하는의약 조성물 |
| CN104109155A (zh) † | 2003-08-01 | 2014-10-22 | 田边三菱制药株式会社 | 新颖化合物 |
| ZA200608028B (en) * | 2004-03-04 | 2009-03-25 | Kissei Pharmaceutical | Fused heterocycle derivative, medicinal composition containing the same, and medicinal use thereof |
| SI1730131T1 (sl) | 2004-03-16 | 2012-08-31 | Boehringer Ingelheim Int | Glukopiranozil-substituirani benzenski derivati, zdravila, ki vsebujejo te spojine, njihova uporaba in postopek za njihovo pripravo |
| US7393836B2 (en) | 2004-07-06 | 2008-07-01 | Boehringer Ingelheim International Gmbh | D-xylopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture |
| EP1773800A1 (de) * | 2004-07-27 | 2007-04-18 | Boehringer Ingelheim International GmbH | D-glucopyranosyl-phenyl-substituierte cyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung |
| US20080139484A1 (en) * | 2004-09-29 | 2008-06-12 | Kissei Pharmaceutical Co., Ltd. | 1(Beta-D-Glycopyranosyl)-3-Substituted Nitrogenous Heterocyclic Compound, Medicinal Composition Containing the Same, and Medicinal Use Thereof |
| ES2314743T3 (es) | 2004-12-16 | 2009-03-16 | Boehringer Ingelheim International Gmbh | Derivados de benceno sustituidos con glucopiranosilo, medicamentos que contienen a este tipo de compuestos, su uso y procedimiento para su fabricacion. |
| TW200637869A (en) | 2005-01-28 | 2006-11-01 | Chugai Pharmaceutical Co Ltd | The spiroketal derivatives and the use as therapeutical agent for diabetes of the same |
| TWI365186B (en) * | 2005-01-31 | 2012-06-01 | Mitsubishi Tanabe Pharma Corp | Indole derivatives |
| JP4496174B2 (ja) * | 2005-01-31 | 2010-07-07 | 田辺三菱製薬株式会社 | 医薬組成物 |
| AR053329A1 (es) * | 2005-01-31 | 2007-05-02 | Tanabe Seiyaku Co | Derivados de indol utiles como inhibidores de los transportadores de glucosa dependientes del sodio (sglt) |
| EP1856082B1 (en) | 2005-02-23 | 2009-10-14 | Boehringer Ingelheim International GmbH | Glucopyranosyl-substituted ((hetero)arylethynyl-benzyl)-benzene derivatives and use thereof as sodium-dependent glucose cotransporter 2 (sglt2) inhibitors |
| WO2006108842A1 (en) | 2005-04-15 | 2006-10-19 | Boehringer Ingelheim International Gmbh | Glucopyranosyl-substituted (heteroaryloxy-benzyl)-benzene derivatives as sglt inhibitors |
| UA91546C2 (uk) | 2005-05-03 | 2010-08-10 | Бьорінгер Інгельхайм Інтернаціональ Гмбх | КРИСТАЛІЧНА ФОРМА 1-ХЛОР-4-(β-D-ГЛЮКОПІРАНОЗ-1-ИЛ)-2-[4-((S)-ТЕТРАГІДРОФУРАН-3-ІЛОКСИ)-БЕНЗИЛ]-БЕНЗОЛУ, СПОСІБ ЇЇ ОДЕРЖАННЯ ТА ЇЇ ЗАСТОСУВАННЯ ПРИ ПРИГОТУВАННІ ЛІКАРСЬКИХ ЗАСОБІВ |
| US7723309B2 (en) | 2005-05-03 | 2010-05-25 | Boehringer Ingelheim International Gmbh | Crystalline forms of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((R)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments |
| US7772191B2 (en) | 2005-05-10 | 2010-08-10 | Boehringer Ingelheim International Gmbh | Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein |
| TW200726755A (en) * | 2005-07-07 | 2007-07-16 | Astellas Pharma Inc | A crystalline choline salt of an azulene derivative |
| JP5128474B2 (ja) | 2005-07-27 | 2013-01-23 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | グルコピラノシル−置換（（ヘテロ）シクロアルキルエチニル−ベンジル）−ベンゼン誘導体、該化合物を含有する薬剤、それらの使用及びそれらの製造方法 |
| JP5175191B2 (ja) | 2005-08-30 | 2013-04-03 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | グリコピラノシル置換ベンジルベンゼン誘導体、該化合物を含有する医薬品及びその使用と製造方法 |
| AU2006289093A1 (en) | 2005-09-08 | 2007-03-15 | Boehringer Ingelheim International Gmbh | Crystalline forms of 1-chloro-4-(beta-D-glucopyranos-1-yl)-2-(4-ethynyl-benzyl)-benzene, methods for its preparation and the use thereof for preparing medicaments |
| AR056195A1 (es) | 2005-09-15 | 2007-09-26 | Boehringer Ingelheim Int | Procedimientos para preparar derivados de (etinil-bencil)-benceno sustituidos de glucopiranosilo y compuestos intermedios de los mismos |
| WO2007093610A1 (en) | 2006-02-15 | 2007-08-23 | Boehringer Ingelheim International Gmbh | Glucopyranosyl-substituted benzonitrile derivatives, pharmaceutical compositions containing such compounds, their use and process for their manufacture |
| TWI370818B (en) | 2006-04-05 | 2012-08-21 | Astellas Pharma Inc | Cocrystal of c-glycoside derivative and l-proline |
| PE20080697A1 (es) | 2006-05-03 | 2008-08-05 | Boehringer Ingelheim Int | Derivados de benzonitrilo sustituidos con glucopiranosilo, composiciones farmaceuticas que contienen compuestos de este tipo, su uso y procedimiento para su fabricacion |
| PE20080251A1 (es) | 2006-05-04 | 2008-04-25 | Boehringer Ingelheim Int | Usos de inhibidores de dpp iv |
| EP2019679B1 (en) | 2006-05-23 | 2018-06-20 | Theracos, Inc. | Glucose transport inhibitors and methods of use |
| TWI432446B (zh) * | 2006-07-27 | 2014-04-01 | Chugai Pharmaceutical Co Ltd | 稠環螺酮縮醇衍生物、及其做為糖尿病治療藥之使用 |
| TWI403516B (zh) * | 2006-07-27 | 2013-08-01 | Chugai Pharmaceutical Co Ltd | To replace spirocyclic alcohol derivatives, and its use as a therapeutic agent for diabetes |
| TWI418556B (zh) * | 2006-07-27 | 2013-12-11 | Mitsubishi Tanabe Pharma Corp | 吲哚衍生物 |
| US20080027014A1 (en) * | 2006-07-28 | 2008-01-31 | Tanabe Seiyaku Co., Ltd. | Novel SGLT inhibitors |
| EP2054426A1 (en) | 2006-08-15 | 2009-05-06 | Boehringer Ingelheim International GmbH | Glucopyranosyl-substituted cyclopropylbenzene derivatives, pharmaceutical compositions containing such compounds, their use as sglt inhibitors and process for their manufacture |
| EP2074130A1 (en) * | 2006-09-21 | 2009-07-01 | Boehringer Ingelheim International GmbH | Glucopyranosyl-substituted difluorobenzyl-benzene derivatives, medicaments containing such compounds, their use and process for their manufacture |
| WO2008044762A1 (fr) | 2006-10-13 | 2008-04-17 | Chugai Seiyaku Kabushiki Kaisha | Dérivé de spirocétal de thioglucose et utilisation de celui-ci comme agent thérapeutique pour le diabète |
| JP2010507629A (ja) | 2006-10-27 | 2010-03-11 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ４−（β−Ｄ−グルコピラノス−１−イル）−１−メチル−２−［４−（（Ｓ）−テトラヒドロフラン−３−イルオキシ）−ベンジル］−ベンゼンの結晶形、その製造方法及び医薬品を製造するための使用 |
| JP5298025B2 (ja) * | 2006-12-04 | 2013-09-25 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | 抗糖尿病薬としてのチエニル含有グリコピラノシル誘導体 |
| UY30730A1 (es) * | 2006-12-04 | 2008-07-03 | Mitsubishi Tanabe Pharma Corp | Forma cristalina del hemihidrato de 1-(b (beta)-d-glucopiranosil) -4-metil-3-[5-(4-fluorofenil) -2-tienilmetil]benceno |
| US8198464B2 (en) | 2006-12-21 | 2012-06-12 | Astellas Pharma Inc. | Method for producing C-glycoside derivative and intermediate for synthesis thereof |
| US7795228B2 (en) * | 2006-12-28 | 2010-09-14 | Theracos, Inc. | Spiroheterocyclic glycosides and methods of use |
| WO2008103618A1 (en) * | 2007-02-22 | 2008-08-28 | University Of Utah Research Foundation | Synthesis of novel xylosides and potential uses thereof |
| WO2008122014A1 (en) * | 2007-04-02 | 2008-10-09 | Theracos, Inc. | Benzylic glycoside derivatives and methods of use |
| EP2146993B1 (en) * | 2007-04-11 | 2015-08-05 | Merck Sharp & Dohme B.V. | A method for the preparation of mirtazapine |
| PE20090938A1 (es) | 2007-08-16 | 2009-08-08 | Boehringer Ingelheim Int | Composicion farmaceutica que comprende un derivado de benceno sustituido con glucopiranosilo |
| KR101107425B1 (ko) | 2007-08-23 | 2012-01-19 | 테라코스, 인코포레이티드 | 벤질벤젠 유도체 및 사용 방법 |
| ME03072B (me) * | 2007-09-10 | 2019-01-20 | Janssen Pharmaceutica Nv | Postupak za dobijanje jedinjenja која su korisna као inhibiтori sgl т |
| UA101004C2 (en) | 2007-12-13 | 2013-02-25 | Теракос, Инк. | Derivatives of benzylphenylcyclohexane and use thereof |
| CL2008003653A1 (es) * | 2008-01-17 | 2010-03-05 | Mitsubishi Tanabe Pharma Corp | Uso de un inhibidor de sglt derivado de glucopiranosilo y un inhibidor de dppiv seleccionado para tratar la diabetes; y composicion farmaceutica. |
| KR101516677B1 (ko) | 2008-01-31 | 2015-05-04 | 고토부키 세이야쿠 가부시키가이샤 | 지방성 간 질환의 치료용 의약 조성물 |
| TW201000494A (en) * | 2008-02-13 | 2010-01-01 | Sanofi Aventis | Novel aromatic fluoroglycoside derivatives, medicaments comprising these compounds and use thereof |
| EP2668953A1 (en) | 2008-05-22 | 2013-12-04 | Bristol-Myers Squibb Company | Pharmaceutical compositions comprising an SGLT2 inhibitor with a supply of carbohydrate and/or an inhibitor of uric acid synthesis |
| WO2010022313A2 (en) | 2008-08-22 | 2010-02-25 | Theracos, Inc. | Processes for the preparation of sglt2 inhibitors |
| EP2334687B9 (en) | 2008-08-28 | 2012-08-08 | Pfizer Inc. | Dioxa-bicyclo[3.2.1.]octane-2,3,4-triol derivatives |
| AU2009294613A1 (en) * | 2008-09-19 | 2010-03-25 | Novartis Ag | Glucoside derivatives and uses thereof as SGLT inhibitors |
| US9056850B2 (en) * | 2008-10-17 | 2015-06-16 | Janssen Pharmaceutica N.V. | Process for the preparation of compounds useful as inhibitors of SGLT |
| RS60438B1 (sr) | 2009-02-13 | 2020-07-31 | Boehringer Ingelheim Int | Farmaceutska kompozicija koja sadrži sglt2 inhibitor, dpp-iv inhibitor i opciono drugo antidijabetičko sredstvo i njihove upotrebe |
| CN101830876A (zh) * | 2009-03-12 | 2010-09-15 | 上海恒瑞医药有限公司 | C-芳基葡萄糖苷衍生物、其制备方法及其在医药上的应用 |
| US20110009347A1 (en) * | 2009-07-08 | 2011-01-13 | Yin Liang | Combination therapy for the treatment of diabetes |
| US8772512B2 (en) | 2009-07-10 | 2014-07-08 | Janssen Pharmaceutica Nv | Crystallisation process for 1-(β-D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl] benzene |
| CN102597770B (zh) | 2009-09-15 | 2016-08-10 | 詹森药业有限公司 | α-甲基葡萄糖苷(AMG)作为葡萄糖吸收和排泄的指示剂的用途 |
| EP2486029B1 (en) | 2009-09-30 | 2015-06-10 | Boehringer Ingelheim International GmbH | Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives |
| JP5736377B2 (ja) | 2009-09-30 | 2015-06-17 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | １−クロロ−４−（β−Ｄ−グルコピラノス−１−イル）−２−［４−（（Ｓ）−テトラヒドロフラン−３−イルオキシ）ベンジル］ベンゼンの結晶形の調製方法 |
| US10610489B2 (en) | 2009-10-02 | 2020-04-07 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, pharmaceutical dosage form, process for their preparation, methods for treating and uses thereof |
| CN102648196B (zh) * | 2009-10-14 | 2016-04-27 | 詹森药业有限公司 | 可用作sglt2的抑制剂的化合物的制备方法 |
| US8163704B2 (en) | 2009-10-20 | 2012-04-24 | Novartis Ag | Glycoside derivatives and uses thereof |
| PT2496583E (pt) | 2009-11-02 | 2015-01-14 | Pfizer | Derivados de dioxa-biciclo[3.2.1]octano-2,3,4-triol |
| CN102115468B (zh) * | 2009-12-31 | 2014-06-11 | 上海特化医药科技有限公司 | 一种2,5-二取代噻吩化合物的合成方法 |
| CN102134226B (zh) * | 2010-01-26 | 2013-06-12 | 天津药物研究院 | 一类苯基c-葡萄糖苷衍生物、其制备方法和用途 |
| EP2552442A1 (en) | 2010-03-30 | 2013-02-06 | Boehringer Ingelheim International GmbH | Pharmaceutical composition comprising an sglt2 inhibitor and a ppar- gamma agonist and uses thereof |
| JP2013523819A (ja) | 2010-04-06 | 2013-06-17 | アリーナ ファーマシューティカルズ， インコーポレイテッド | Ｇｐｒ１１９レセプターのモジュレーターおよびそれに関連する障害の処置 |
| MX339570B (es) | 2010-05-11 | 2016-05-31 | Janssen Pharmaceutica Nv | Formulaciones farmaceuticas que comprenden derivados de 1-(beta-d-glucopiranosil)-2-tienil-metilbenceno como inhibidores de transportadores de glucosa dependientes de sodio. |
| WO2011142478A1 (en) | 2010-05-11 | 2011-11-17 | Mitsubishi Tanabe Pharma Corporation | Canagliflozin containing tablets |
| US8217183B2 (en) | 2010-05-18 | 2012-07-10 | Corning Incorporated | Methods of making fused thiophenes |
| WO2011153712A1 (en) | 2010-06-12 | 2011-12-15 | Theracos, Inc. | Crystalline form of benzylbenzene sglt2 inhibitor |
| TWI541030B (zh) | 2010-07-06 | 2016-07-11 | 健生藥品公司 | 用於糖尿病協同治療之調配物 |
| CN102372722A (zh) | 2010-08-10 | 2012-03-14 | 江苏恒瑞医药股份有限公司 | C-芳基葡萄糖苷衍生物、其制备方法及其在医药上的应用 |
| US9006187B2 (en) * | 2010-09-10 | 2015-04-14 | Green Cross Corporation | Thiophene derivative as SGLT2 inhibitor and pharmaceutical composition comprising same |
| PE20131371A1 (es) | 2010-09-22 | 2013-11-25 | Arena Pharm Inc | Moduladores del receptor gpr119 y el tratamiento de trastornos relacionados con este |
| WO2012041898A1 (en) | 2010-09-29 | 2012-04-05 | Celon Pharma Sp. Z O.O. | Combination of sglt2 inhibitor and a sugar compound for the treatment of diabetes |
| CN102453026A (zh) | 2010-10-27 | 2012-05-16 | 上海艾力斯医药科技有限公司 | C-芳基葡糖苷衍生物、制备方法及其应用 |
| US20120283169A1 (en) | 2010-11-08 | 2012-11-08 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
| US20130035281A1 (en) | 2011-02-09 | 2013-02-07 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
| EP2676965B1 (en) | 2011-02-18 | 2017-10-04 | Shanghai Yingli Pharmaceutical Co., Ltd | Aryl glycoside compound, preparation method and use thereof |
| AR085689A1 (es) | 2011-03-07 | 2013-10-23 | Boehringer Ingelheim Int | Composiciones farmaceuticas de metformina, linagliptina y un inhibidor de sglt-2 |
| WO2012135570A1 (en) | 2011-04-01 | 2012-10-04 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
| US9487506B2 (en) | 2011-04-13 | 2016-11-08 | Merck Sharp & Dohme Corp. | Mineralocorticoid receptor antagonists |
| EA028946B1 (ru) | 2011-04-13 | 2018-01-31 | Янссен Фармацевтика Нв | Способ получения соединений для применения в качестве ингибиторов sglt2 |
| JP2014510782A (ja) * | 2011-04-14 | 2014-05-01 | ノバルティス アーゲー | グリコシド誘導体およびその使用 |
| US20140066369A1 (en) | 2011-04-19 | 2014-03-06 | Arena Pharmaceuticals, Inc. | Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto |
| WO2012145604A1 (en) | 2011-04-22 | 2012-10-26 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
| US20140038889A1 (en) | 2011-04-22 | 2014-02-06 | Arena Pharmaceuticals, Inc. | Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto |
| US9035044B2 (en) | 2011-05-09 | 2015-05-19 | Janssen Pharmaceutica Nv | L-proline and citric acid co-crystals of (2S, 3R, 4R, 5S,6R)-2-(3-((5-(4-fluorophenyl)thiopen-2-yl)methyl)4-methylphenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol |
| JP6117186B2 (ja) * | 2011-05-20 | 2017-04-19 | ヤンセン ファーマシューティカ エヌ．ベー． | Ｓｇｌｔ−２の阻害物質として有用な化合物の製造方法 |
| CA2836661A1 (en) * | 2011-05-20 | 2012-11-29 | Janssen Pharmaceutica Nv | Process for the preparation of compounds useful as inhibitors of sglt-2 |
| US9034921B2 (en) * | 2011-06-01 | 2015-05-19 | Green Cross Corporation | Diphenylmethane derivatives as SGLT2 inhibitors |
| AU2012264736A1 (en) | 2011-06-03 | 2013-11-28 | Boehringer Ingelheim International Gmbh | SGLT-2 inhibitors for treating metabolic disorders in patients treated with neuroleptic agents |
| WO2012170702A1 (en) | 2011-06-08 | 2012-12-13 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
| CN102827122B (zh) * | 2011-06-17 | 2015-01-14 | 山东轩竹医药科技有限公司 | 糖苷衍生物 |
| WO2013055910A1 (en) | 2011-10-12 | 2013-04-18 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
| WO2013061105A2 (en) * | 2011-10-28 | 2013-05-02 | Debreceni Egyetem | Glycogen phosphorylase inhibitors |
| US8697658B2 (en) | 2011-12-15 | 2014-04-15 | National Health Research Institutes | Glycoside compounds |
| US9555001B2 (en) | 2012-03-07 | 2017-01-31 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition and uses thereof |
| US9192617B2 (en) | 2012-03-20 | 2015-11-24 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
| US9193751B2 (en) | 2012-04-10 | 2015-11-24 | Theracos, Inc. | Process for the preparation of benzylbenzene SGLT2 inhibitors |
| CN103570671B (zh) * | 2012-09-26 | 2016-03-30 | 上海天慈生物谷生物工程有限公司 | 一种降糖化合物及其制法和应用 |
| WO2014074668A1 (en) | 2012-11-08 | 2014-05-15 | Arena Pharmaceuticals, Inc. | Modulators of gpr119 and the treatment of disorders related thereto |
| WO2014094544A1 (zh) * | 2012-12-17 | 2014-06-26 | 天津药物研究院 | 含脱氧葡萄糖结构的苯基c-葡萄糖苷衍生物及其制备方法和用途 |
| CN103910769B (zh) | 2012-12-31 | 2018-10-02 | 上海璎黎药业有限公司 | 葡萄糖衍生物和脯氨酸的复合物、晶体、制备方法及应用 |
| JP6173427B2 (ja) * | 2013-02-26 | 2017-08-02 | 田辺三菱製薬株式会社 | α−ハロテトラアシルグルコースの製造方法 |
| JP6461080B2 (ja) * | 2013-03-11 | 2019-01-30 | ヤンセン ファーマシューティカ エヌ．ベー． | 二重ｓｇｌｔ１／ｓｇｌｔ２阻害剤 |
| EP2968375B1 (en) | 2013-03-14 | 2019-06-12 | MSD International GmbH | Methods for preparing sglt2 inhibitors |
| WO2014149789A1 (en) | 2013-03-15 | 2014-09-25 | Janssen Pharmaceutica Nv | Combination of canagliflozin and probenecid for the treament of hyperuricemia |
| DK2981269T3 (da) | 2013-04-04 | 2023-10-23 | Boehringer Ingelheim Vetmedica Gmbh | Behandling af stofskifteforstyrrelser hos hestedyr |
| US11813275B2 (en) | 2013-04-05 | 2023-11-14 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
| PT2981271T (pt) | 2013-04-05 | 2019-02-19 | Boehringer Ingelheim Int | Utilizações terapêuticas de empagliflozina |
| US20140303097A1 (en) | 2013-04-05 | 2014-10-09 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
| CN105377266A (zh) | 2013-04-18 | 2016-03-02 | 勃林格殷格翰国际有限公司 | 药物组合物、治疗方法及其用途 |
| WO2014180872A1 (en) | 2013-05-08 | 2014-11-13 | Lek Pharmaceuticals D.D. | NOVEL CRYSTALLINE HYDRATES OF 1-(ß-D-GLUCOPYRANOSYL)-4-METHYL-3-[5-(4-FLUOROPHENYL)-2-THIENYLMETHYL]BENZENE |
| WO2014195966A2 (en) | 2013-05-30 | 2014-12-11 | Cadila Healthcare Limited | Amorphous form of canagliflozin and process for preparing thereof |
| CN104418834B (zh) * | 2013-08-23 | 2017-09-15 | 重庆博腾制药科技股份有限公司 | 一种抗糖尿病药物中间体的合成方法 |
| CN105611920B (zh) | 2013-10-12 | 2021-07-16 | 泰拉科斯萨普有限责任公司 | 羟基-二苯甲烷衍生物的制备 |
| CN104557894A (zh) * | 2013-10-18 | 2015-04-29 | 上海信谊药厂有限公司 | 坎格列汀晶型及其制备方法 |
| SI3862003T1 (sl) | 2013-12-17 | 2024-02-29 | Boehringer Ingelheim Vetmedica Gmbh | Inhibitor SGLT-2 za uporabo pri zdravljenju metabolične motnje pri mačjih živalih |
| WO2015110402A1 (en) | 2014-01-23 | 2015-07-30 | Boehringer Ingelheim Vetmedica Gmbh | Treatment of metabolic disorders in canine animals |
| WO2015116880A1 (en) | 2014-01-31 | 2015-08-06 | Janssen Pharmaceutica Nv | Methods for the treatment and prevention of renal disorders and fatty liver disorders |
| EP2918579A1 (en) | 2014-03-14 | 2015-09-16 | LEK Pharmaceuticals d.d. | Synthesis of 2-arylmethyl-5-aryl-thiophene |
| WO2015139386A1 (zh) | 2014-03-19 | 2015-09-24 | 杭州普晒医药科技有限公司 | 坎格列净一水合物及其晶型、它们的制备方法和用途 |
| CN103936725B (zh) * | 2014-04-01 | 2016-07-27 | 天津大学 | 卡格列净的c晶型及其结晶制备方法 |
| PL3125882T3 (pl) | 2014-04-01 | 2020-10-19 | Boehringer Ingelheim Vetmedica Gmbh | Leczenie zaburzeń metabolicznych u zwierząt koniowatych |
| CN105001213B (zh) | 2014-04-14 | 2020-08-28 | 上海迪诺医药科技有限公司 | C-芳基糖苷衍生物、其药物组合物、制备方法及应用 |
| CN103980263B (zh) * | 2014-04-17 | 2016-08-03 | 海门瑞一医药科技有限公司 | 卡格列净的合成工艺 |
| EP2933255A1 (en) | 2014-04-17 | 2015-10-21 | LEK Pharmaceuticals d.d. | Novel crystalline form of 1-(beta-D-glucopyranosyl)-4- methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene |
| CN103936800A (zh) * | 2014-05-08 | 2014-07-23 | 安徽联创药物化学有限公司 | 1-(1-甲氧基吡喃葡糖基)-4-甲基-3-[5-(4-氟苯基)-2-噻吩基甲基]苯的制备方法 |
| TW201623321A (zh) * | 2014-05-13 | 2016-07-01 | 韓美藥品股份有限公司 | 雙環衍生物及包含其之藥學組成物 |
| EP2947077A1 (en) | 2014-05-19 | 2015-11-25 | LEK Pharmaceuticals d.d. | Stereoselective synthesis of intermediates in the preparation of ß-C-arylglucosides |
| WO2015181692A1 (en) * | 2014-05-27 | 2015-12-03 | Glenmark Pharmaceuticals Limited | Process for preparation of canagliflozin |
| CN105319294B (zh) * | 2014-06-20 | 2021-03-30 | 重庆医药工业研究院有限责任公司 | 一种分离测定卡格列净及其有关物质的方法 |
| US20160002275A1 (en) * | 2014-07-03 | 2016-01-07 | Cadila Healthcare Limited | Process for preparation and purification of canagliflozin |
| CN104119324B (zh) * | 2014-07-23 | 2016-03-30 | 齐鲁天和惠世制药有限公司 | 一种卡格列净的制备方法 |
| CN104109157B (zh) * | 2014-08-04 | 2016-05-25 | 山东康美乐医药科技有限公司 | 卡格列净的制备方法 |
| EP2990029A1 (en) | 2014-08-29 | 2016-03-02 | Sandoz Ag | Pharmaceutical compositions comprising Canagliflozin |
| WO2016035042A1 (en) | 2014-09-05 | 2016-03-10 | Mylan Laboratories Ltd | Process for the preparation of canagliflozin |
| CN104292209A (zh) * | 2014-09-11 | 2015-01-21 | 浙江丽晶化学有限公司 | 一种制备2-(4-氟苯基)噻吩(化合物v)的新方法 |
| CZ2014634A3 (cs) | 2014-09-16 | 2016-03-23 | Zentiva, K.S. | Komplexy canagliflozinu a cyklodextrinů |
| CN104817554A (zh) * | 2014-11-10 | 2015-08-05 | 镇江新元素医药科技有限公司 | 一类葡萄糖苷衍生物及其药物组合物 |
| CN104447906A (zh) * | 2015-01-14 | 2015-03-25 | 佛山市赛维斯医药科技有限公司 | 烷氧苯基双葡萄糖苷衍生物、其制备方法和用途 |
| CN104447907A (zh) * | 2015-01-14 | 2015-03-25 | 佛山市赛维斯医药科技有限公司 | 含硝基联苯双葡萄糖苷结构化合物、其制备方法和用途 |
| CN104478968A (zh) * | 2015-01-14 | 2015-04-01 | 佛山市赛维斯医药科技有限公司 | 含噻唑基的o-半乳糖苷衍生物、其制备方法和用途 |
| CN104447905A (zh) * | 2015-01-14 | 2015-03-25 | 佛山市赛维斯医药科技有限公司 | 一种含硝基苯和双o-葡萄糖苷衍生物、其制备方法和用途 |
| CN104478969A (zh) * | 2015-01-14 | 2015-04-01 | 佛山市赛维斯医药科技有限公司 | 含烷氧苯基噻唑基的o-半乳糖苷衍生物、其制备方法和用途 |
| CN104478962A (zh) * | 2015-01-15 | 2015-04-01 | 佛山市赛维斯医药科技有限公司 | 一类卤代苯基s-葡萄糖苷衍生物、其制备方法和用途 |
| EP3256482B1 (en) | 2015-02-09 | 2019-11-27 | Indoco Remedies Limited | Process for the preparation of sglt inhibitor compounds |
| CN105884755B (zh) * | 2015-02-14 | 2019-05-28 | 正大天晴药业集团股份有限公司 | 氘修饰的碳甙衍生物 |
| JP6508324B2 (ja) * | 2015-02-19 | 2019-05-08 | Jnc株式会社 | ベンゾチオフェンを有する液晶性化合物、液晶組成物および液晶表示素子 |
| WO2016135747A2 (en) * | 2015-02-27 | 2016-09-01 | Msn Laboratories Private Limited | Process for the preparation of amorphous (1s)-1,5-anhvdro-1-[3-[[5-(4 fluorophennyl)-2-thienyl]methvl]-4-methylphenyl]-d-glucitol and its polymorphs thereof |
| CN104803977A (zh) * | 2015-03-03 | 2015-07-29 | 佛山市赛维斯医药科技有限公司 | 一种含四氮唑结构的ptp1b衍生物、其制备方法及用途 |
| WO2016142950A1 (en) * | 2015-03-11 | 2016-09-15 | Harman Finochem Limited | A novel process for preparing (2s,3r,4r,5s,6r)-2-{3-[5-[4-fluoro-phenyl)- thiophen-2-ylmethyl]-4-methyl-phenyl}-6-hydroxymethyl-tetrahydro-pyran-3,4,5- triol and its stable amorphous hemihydrate form |
| JP6916740B2 (ja) | 2015-05-22 | 2021-08-11 | ヤンセン ファーマシューティカ エヌ．ベー． | （１ｓ）−１，５−アンヒドロ−１−［３−［［５−（４−フルオロフェニル）−２−チエニル］メチル］−４−メチルフェニル］−ｄ−グルシトールの無水結晶形 |
| CN104926803B (zh) * | 2015-06-17 | 2017-12-22 | 南通常佑药业科技有限公司 | 一种新的sglt2抑制剂药物的制备方法 |
| CZ2015435A3 (cs) | 2015-06-25 | 2017-01-04 | Zentiva, K.S. | Pevné formy amorfního canagliflozinu |
| CN104987320A (zh) * | 2015-08-03 | 2015-10-21 | 沧州那瑞化学科技有限公司 | 一种坎格列净中间体的制备方法 |
| US20170071970A1 (en) | 2015-09-15 | 2017-03-16 | Janssen Pharmaceutica Nv | Co-therapy comprising canagliflozin and phentermine for the treatment of obesity and obesity related disorders |
| ES2896101T3 (es) | 2015-09-15 | 2022-02-23 | Laurus Labs Ltd | Cocristales de inhibidores de SGLT2, procedimiento para su preparación y composiciones farmacéuticas de los mismos |
| US10370365B2 (en) | 2015-09-16 | 2019-08-06 | Optimus Drugs (P) Limited | Process for the preparation of Canagliflozin |
| WO2017046655A1 (en) * | 2015-09-16 | 2017-03-23 | Optimus Drugs (P) Ltd | A novel process for the preparation of canagliflozin |
| CZ2015729A3 (cs) | 2015-10-13 | 2017-04-26 | Zentiva, K.S. | Příprava intermediátů pro syntézu Canagliflozinu a Dapagliflozinu |
| WO2017064679A1 (en) * | 2015-10-15 | 2017-04-20 | Lupin Limited | Process for the preparation of amorphous canagliflozin |
| CN105503845A (zh) * | 2015-12-01 | 2016-04-20 | 北京普德康利医药科技发展有限公司 | 去氟卡格列净化合物及其制备方法和应用 |
| WO2017093949A1 (en) * | 2015-12-04 | 2017-06-08 | Dr. Reddy's Laboratories Limited | Substantially pure canagliflozin |
| CN106892929B (zh) * | 2015-12-17 | 2020-01-14 | 上海艾力斯医药科技有限公司 | 螺缩酮衍生物及其制备方法和应用 |
| CA3006237C (en) | 2015-12-21 | 2023-10-03 | Janssen Pharmaceutica Nv | Crystallization procedure for obtaining canagliflozin hemihydrate crystals |
| CN105541815B (zh) * | 2015-12-24 | 2018-07-13 | 寿光富康制药有限公司 | 一种卡格列净的制备方法 |
| WO2017141202A1 (en) | 2016-02-17 | 2017-08-24 | Lupin Limited | Complex of sglt2 inhibitor and process for preparation thereof |
| TN2018000437A1 (en) * | 2016-06-17 | 2020-06-15 | Dae Woong Pharma | Method for producing diphenylmethane derivative |
| WO2018020506A1 (en) | 2016-07-25 | 2018-02-01 | Natco Pharma Ltd | Process for the preparation of amorphous form of canagliflozin |
| US20210212968A1 (en) | 2016-10-19 | 2021-07-15 | Boehringer Ingelheim International Gmbh | Combinations comprising an ssao/vap-1 inhibitor and a sglt2 inhibitor, uses thereof |
| CN106588898A (zh) | 2017-02-20 | 2017-04-26 | 浙江华海药业股份有限公司 | 一种卡格列净无定型的制备方法 |
| WO2018207111A1 (en) | 2017-05-09 | 2018-11-15 | Piramal Enterprises Limited | A process for the preparation of sglt2 inhibitors and intermediates thereof |
| KR20200014406A (ko) | 2017-06-12 | 2020-02-10 | 얀센 파마슈티카 엔.브이. | Ii형 진성 당뇨병을 갖는 환자에서 심혈관 사건을 감소시키거나 예방하는 방법 |
| CN108017612B (zh) * | 2017-11-29 | 2020-06-09 | 南通常佑药业科技有限公司 | 一种坎格列净中间体的制备方法 |
| JP2021520394A (ja) | 2018-04-17 | 2021-08-19 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 医薬組成物、処置方法及びその使用 |
| EP3823631A1 (en) | 2018-07-19 | 2021-05-26 | Astrazeneca AB | Methods of treating hfpef employing dapagliflozin and compositions comprising the same |
| WO2020039394A1 (en) | 2018-08-24 | 2020-02-27 | Novartis Ag | New drug combinations |
| WO2020050361A1 (ja) * | 2018-09-06 | 2020-03-12 | 株式会社トクヤマ | β－Ｃ－アリールグリコシド誘導体の製造方法 |
| CA3118629A1 (en) | 2018-11-05 | 2020-05-14 | Balticgruppen Bio Ab | Methods of treating diabetes in severe insulin-resistant diabetic subjects |
| TW202103709A (zh) | 2019-03-26 | 2021-02-01 | 比利時商健生藥品公司 | 用於治療患有慢性腎臟病之對象的方法 |
| US11759474B2 (en) | 2019-11-28 | 2023-09-19 | Boehringer Ingelheim Vetmedica Gmbh | Use of SGLT-2 inhibitors in the drying-off of non-human mammals |
| CN110981851A (zh) * | 2019-12-24 | 2020-04-10 | 艾希尔（深圳）药物研发有限公司 | 一种卡格列净杂质的制备方法 |
| KR20220143732A (ko) | 2020-02-17 | 2022-10-25 | 베링거잉겔하임베트메디카게엠베하 | 고양이과에서 심장 질환을 예방 및/또는 치료하기 위한 sglt-2 억제제의 사용 |
| CN115916197A (zh) | 2020-04-22 | 2023-04-04 | 拜耳公司 | 用于治疗和/或预防心血管和/或肾脏疾病的非奈利酮和sglt2抑制剂的组合 |
| WO2022022865A1 (en) | 2020-07-27 | 2022-02-03 | Astrazeneca Ab | Methods of treating chronic kidney disease with dapagliflozin |
| WO2022208172A1 (en) | 2021-04-01 | 2022-10-06 | Astrazeneca Uk Limited | Systems and methods for managing prediabetes with a gliflozin sodium-glucose cotransport 2 inhibitor pharmaceutical composition |
| CN113429379A (zh) * | 2021-06-28 | 2021-09-24 | 江苏法安德医药科技有限公司 | 一种lh-1801中间体及其制备方法和应用 |
| CA3223537A1 (en) | 2021-07-28 | 2023-02-02 | Boehringer Ingelheim Vetmedica Gmbh | Use of sglt-2 inhibitors for the prevention and/or treatment of cardiac diseases in non-human mammals excluding felines, in particular canines |
| AU2022318037A1 (en) | 2021-07-28 | 2024-02-22 | Boehringer Ingelheim Vetmedica Gmbh | Use of sglt-2 inhibitors for the prevention and/or treatment of renal diseases in non-human mammals |
| EP4376819A1 (en) | 2021-07-28 | 2024-06-05 | Boehringer Ingelheim Vetmedica GmbH | Use of sglt-2 inhibitors for the prevention and/or treatment of hypertension in non-human mammals |
| WO2023129595A1 (en) | 2021-12-30 | 2023-07-06 | Newamsterdam Pharma B.V. | Obicetrapib and sglt2 inhibitor combination |
| WO2023144722A1 (en) | 2022-01-26 | 2023-08-03 | Astrazeneca Ab | Dapagliflozin for use in the treatment of prediabetes or reducing the risk of developing type 2 diabetes |
| US20230381101A1 (en) | 2022-05-25 | 2023-11-30 | Boehringer Ingelheim Vetmedica Gmbh | Aqueous pharmaceutical compositions comprising sglt-2 inhibitors |
Family Cites Families (70)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR1476537A (fr) * | 1965-05-10 | 1967-04-14 | Chimetron Sarl | Glucosides dérivés du benzimidazole |
| US4160861A (en) | 1977-10-03 | 1979-07-10 | Merck & Co., Inc. | Method for the separation of antibiotic macrolides |
| US4584369A (en) | 1981-07-31 | 1986-04-22 | Sloan-Kettering Institute For Cancer Research | Anti-leukemic beta-glycosyl C-nucleosides |
| JP2544609B2 (ja) | 1986-10-07 | 1996-10-16 | 和光純薬工業株式会社 | Ｔｃｎｑ錯体 |
| CA1334969C (en) | 1988-08-19 | 1995-03-28 | Mark James Suto | Substituted dihydroisoquinoline and phthalazine derivatives as potentiators of the lethal effects of radiation and certain chemotherapeutic agents, selected compounds, analogs andprocess |
| HU203896B (en) | 1988-10-26 | 1991-10-28 | Biogal Gyogyszergyar | Process for producing glycosides of aromatic amines |
| JPH04253974A (ja) | 1991-02-05 | 1992-09-09 | Ishihara Sangyo Kaisha Ltd | スルホニル尿素系化合物、それらの製造方法及びそれらを含有する除草剤 |
| US5149838A (en) | 1991-09-20 | 1992-09-22 | Merck & Co., Inc. | Intermediates for substituted azetidinones useful as anti-inflammatory and antidegenerative agents |
| GB9208161D0 (en) | 1992-04-14 | 1992-05-27 | Pfizer Ltd | Indoles |
| US5334225A (en) | 1992-07-15 | 1994-08-02 | Kao Corporation | Keratinous fiber dye composition containing a 2-substituted amino-5-alkylphenol derivative coupler |
| CA2102591C (en) * | 1992-11-12 | 2000-12-26 | Kenji Tsujihara | Hypoglycemic agent |
| US5731292A (en) | 1992-11-12 | 1998-03-24 | Tanabe Seiyaku Co., Ltd. | Dihydrochalcone derivatives which are hypoglycemic agents |
| US6297363B1 (en) | 1993-02-12 | 2001-10-02 | Nomura Co., Ltd. | Glycoside indoles |
| US5830873A (en) | 1994-05-11 | 1998-11-03 | Tanabe Seiyaku Co., Ltd. | Propiophenone derivative and a process for preparing the same |
| US5780483A (en) | 1995-02-17 | 1998-07-14 | Smithkline Beecham Corporation | IL-8 receptor antagonists |
| CA2236007A1 (en) | 1995-10-31 | 1997-07-17 | Gerald Floyd Smith | Antithrombotic diamines |
| JP3059088B2 (ja) * | 1995-11-07 | 2000-07-04 | 田辺製薬株式会社 | プロピオフェノン誘導体およびその製法 |
| JPH09263549A (ja) | 1996-01-25 | 1997-10-07 | Fujisawa Pharmaceut Co Ltd | ベンゼン誘導体の製造法 |
| ATE216704T1 (de) * | 1996-12-26 | 2002-05-15 | Tanabe Seiyaku Co | Propiophenonderivate und verfahren zu ihrer herstellung |
| US6153632A (en) | 1997-02-24 | 2000-11-28 | Rieveley; Robert B. | Method and composition for the treatment of diabetes |
| JPH10324632A (ja) | 1997-03-25 | 1998-12-08 | Takeda Chem Ind Ltd | 医薬組成物 |
| JP2000034239A (ja) | 1998-07-16 | 2000-02-02 | Asahi Glass Co Ltd | トリフルオロメチル化芳香族化合物の製造方法 |
| JP3857429B2 (ja) | 1998-07-17 | 2006-12-13 | ポーラ化成工業株式会社 | 含硫黄抗真菌剤 |
| US20020032164A1 (en) | 1998-12-30 | 2002-03-14 | Dale Roderic M. K. | Antimicrobial compounds and methods for their use |
| GB9912961D0 (en) | 1999-06-03 | 1999-08-04 | Pfizer Ltd | Metalloprotease inhibitors |
| US6515117B2 (en) | 1999-10-12 | 2003-02-04 | Bristol-Myers Squibb Company | C-aryl glucoside SGLT2 inhibitors and method |
| PH12000002657B1 (en) | 1999-10-12 | 2006-02-21 | Bristol Myers Squibb Co | C-aryl glucoside SGLT2 inhibitors |
| JP4456768B2 (ja) | 2000-02-02 | 2010-04-28 | 壽製薬株式会社 | Ｃ−配糖体を含有する薬剤 |
| US6627611B2 (en) * | 2000-02-02 | 2003-09-30 | Kotobuki Pharmaceutical Co Ltd | C-glycosides and preparation of thereof as antidiabetic agents |
| EP1259504A1 (en) | 2000-03-03 | 2002-11-27 | Pfizer Products Inc. | Pyrazole ether derivatives as anti-inflammatory/analgesic agents |
| TR200202200T2 (tr) | 2000-03-17 | 2002-12-23 | Kissei Pharmaceutical Co., Ltd. | Glükopiranosiloksibenzilbenzen türevleri, bu türevleri ihtiva eden tıbbi bileşimler ve türevlerin hazırlanması için ara-maddeler. |
| US6683056B2 (en) * | 2000-03-30 | 2004-01-27 | Bristol-Myers Squibb Company | O-aryl glucoside SGLT2 inhibitors and method |
| US6555519B2 (en) | 2000-03-30 | 2003-04-29 | Bristol-Myers Squibb Company | O-glucosylated benzamide SGLT2 inhibitors and method |
| ATE455785T1 (de) | 2000-11-02 | 2010-02-15 | Ajinomoto Kk | Neue pyrazolderivate und diese enthaltende mittel gegen diabetes |
| US6476352B2 (en) | 2000-12-18 | 2002-11-05 | General Electric Company | Laser beam stop sensor and method for automatically detecting the presence of laser beam stop material using a laser beam stop sensor |
| CZ305971B6 (cs) | 2000-12-28 | 2016-06-01 | Kissei Pharmaceutical Co., Ltd. | Deriváty glukopyranosyloxypyrazolu a jejich použití v léčivech |
| EP1364957B1 (en) | 2001-02-26 | 2008-12-31 | Kissei Pharmaceutical Co., Ltd. | Glycopyranosyloxypyrazole derivatives and medicinal use thereof |
| WO2002068440A1 (fr) | 2001-02-27 | 2002-09-06 | Kissei Pharmaceutical Co., Ltd. | Derives de glycopyranosyloxypyrazole et utilisation medicinale de ceux-ci |
| EP1363954B1 (en) | 2001-03-02 | 2012-10-17 | University of Western Ontario | Polymer precursors of radiolabeled compounds, and methods of making and using the same |
| US6936590B2 (en) * | 2001-03-13 | 2005-08-30 | Bristol Myers Squibb Company | C-aryl glucoside SGLT2 inhibitors and method |
| ATE318272T1 (de) * | 2001-04-11 | 2006-03-15 | Bristol Myers Squibb Co | Aminosäurekomplexe von c-arylglycosiden zur behandlung von diabetes und verfahren |
| CA2445346C (en) | 2001-04-27 | 2010-04-06 | Ajinomoto Co., Inc. | N-substituted pyrazole-o-glycoside derivatives and therapeutic agent for diabetes containing the same |
| GB0112122D0 (en) | 2001-05-18 | 2001-07-11 | Lilly Co Eli | Heteroaryloxy 3-substituted propanamines |
| EP1405859A4 (en) | 2001-06-20 | 2008-01-23 | Kissei Pharmaceutical | NITROGENIC HETEROCYCLIC DERIVATIVE, MEDICAL COMPOSITION, MEDICAL USE AND INTERMEDIATE PRODUCTS CONTAINING THEREOF |
| JP4115105B2 (ja) | 2001-07-02 | 2008-07-09 | 協和醗酵工業株式会社 | ピラゾール誘導体 |
| WO2003011880A1 (fr) | 2001-07-31 | 2003-02-13 | Kissei Pharmaceutical Co., Ltd. | Derive de glucopyranosyloxybenzylbenzene, composition medicinale contenant ce derive, usage medicinal de cette composition et produit intermediaire pour produire cette composition |
| WO2003020737A1 (en) | 2001-09-05 | 2003-03-13 | Bristol-Myers Squibb Company | O-pyrazole glucoside sglt2 inhibitors and method of use |
| DE60208809T2 (de) | 2001-10-24 | 2006-11-02 | Michael Warrington Burton | Enzymsubstrate zum Nachweis der ß-D-Ribofuranosidase-Aktivität |
| BR0214208A (pt) | 2001-11-16 | 2004-10-26 | Cutanix Corp | Composições farmacêuticas e cosméticas que contêm aldeìdos aromáticos que suportam grupos de oxigênio |
| US6617313B1 (en) | 2002-03-13 | 2003-09-09 | Council Of Scientific And Industrial Research | Glucopyranoside and process of isolation thereof from pterocarpus marsupium pharmaceutical composition containing the same and use thereof |
| US6562791B1 (en) * | 2002-03-29 | 2003-05-13 | Council Of Scientific And Industrial Research | Glucopyranoside, process for isolation thereof, pharmaceutical composition containing same and use thereof |
| AU2003224546B2 (en) | 2002-04-18 | 2008-11-06 | Astrazeneca Ab | Heterocyclic compounds |
| DE10230605A1 (de) | 2002-07-08 | 2004-01-29 | Bayer Ag | Substituierte Imidazotriazine |
| DE10231370B4 (de) | 2002-07-11 | 2006-04-06 | Sanofi-Aventis Deutschland Gmbh | Thiophenglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel |
| TWI254635B (en) | 2002-08-05 | 2006-05-11 | Yamanouchi Pharma Co Ltd | Azulene derivative and salt thereof |
| JP3813160B2 (ja) | 2002-08-09 | 2006-08-23 | 大正製薬株式会社 | アリール５−チオ−β−Ｄ−グルコピラノシド誘導体及びそれを含有する糖尿病治療薬 |
| JP4606876B2 (ja) | 2002-08-27 | 2011-01-05 | キッセイ薬品工業株式会社 | ピラゾール誘導体、それを含有する医薬組成物及びその医薬用途 |
| DE10258008B4 (de) | 2002-12-12 | 2006-02-02 | Sanofi-Aventis Deutschland Gmbh | Heterocyclische Fluorglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel |
| DE10258007B4 (de) | 2002-12-12 | 2006-02-09 | Sanofi-Aventis Deutschland Gmbh | Aromatische Fluorglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel |
| AU2003299966A1 (en) | 2003-01-03 | 2004-08-10 | Bristol-Myers Squibb Company | Methods of producing c-aryl glucoside sglt2 inhibitors |
| KR101001850B1 (ko) * | 2003-03-14 | 2010-12-17 | 고토부키 세이야쿠 가부시키가이샤 | Ｃ-글리코시드 유도체 또는 이의 염, 및 이를 포함하는의약 조성물 |
| JP2004300102A (ja) | 2003-03-31 | 2004-10-28 | Kissei Pharmaceut Co Ltd | 縮合複素環誘導体、それを含有する医薬組成物およびその医薬用途 |
| AU2003902263A0 (en) | 2003-05-12 | 2003-05-29 | Fujisawa Pharmaceutical Co., Ltd. | Monosaccharide compounds |
| JP4708187B2 (ja) | 2003-06-20 | 2011-06-22 | キッセイ薬品工業株式会社 | ピラゾール誘導体、それを含有する医薬組成物及びその製造中間体 |
| WO2005011592A2 (en) | 2003-08-01 | 2005-02-10 | Janssen Pharmaceutica N.V. | Substituted indazole-o-glucosides |
| EA009768B1 (ru) | 2003-08-01 | 2008-04-28 | Янссен Фармацевтика Нв | Замещенные конденсированные гетероциклические с-гликозиды |
| CN104109155A (zh) † | 2003-08-01 | 2014-10-22 | 田边三菱制药株式会社 | 新颖化合物 |
| WO2005012243A2 (en) | 2003-08-01 | 2005-02-10 | Janssen Pharmaceutica N.V. | Substituted indole-o-glucosides |
| US7094764B2 (en) | 2003-08-01 | 2006-08-22 | Janssen Pharmaceutica N.V. | Substituted benzimidazole-, Benztriazole-, and benzimidazolone-O-glucosides |
| UA86042C2 (en) | 2003-08-01 | 2009-03-25 | Янссен Фармацевтика Н.В. | Substituted indazole-o-glucosides |
-
2004
- 2004-07-30 CN CN201410105650.2A patent/CN104109155A/zh active Pending
- 2004-07-30 EP EP14194507.1A patent/EP2896397B2/en active Active
- 2004-07-30 LT LTEP14194507.1T patent/LT2896397T/lt unknown
- 2004-07-30 NZ NZ575711A patent/NZ575711A/en not_active IP Right Cessation
- 2004-07-30 KR KR1020067002144A patent/KR100778988B1/ko active Protection Beyond IP Right Term
- 2004-07-30 MX MXPA06001274A patent/MXPA06001274A/es active IP Right Grant
- 2004-07-30 AR ARP040102718A patent/AR045173A1/es active IP Right Grant
- 2004-07-30 JP JP2006519251A patent/JP4130466B2/ja active Active
- 2004-07-30 KR KR1020077013086A patent/KR100942622B1/ko not_active IP Right Cessation
- 2004-07-30 AU AU2004260761A patent/AU2004260761B2/en active Active
- 2004-07-30 ME MEP-2008-612A patent/ME00411B/me unknown
- 2004-07-30 EP EP04771314.4A patent/EP1651658B2/en active Active
- 2004-07-30 EA EA200600351A patent/EA010299B1/ru active Protection Beyond IP Right Term
- 2004-07-30 SI SI200432007T patent/SI1651658T2/sl unknown
- 2004-07-30 ES ES12176099.5T patent/ES2531660T3/es active Active
- 2004-07-30 TW TW099122097A patent/TWI385177B/zh not_active IP Right Cessation
- 2004-07-30 PT PT141945071T patent/PT2896397T/pt unknown
- 2004-07-30 CN CN201310561692.2A patent/CN103819465A/zh active Pending
- 2004-07-30 WO PCT/JP2004/011312 patent/WO2005012326A1/en active Application Filing
- 2004-07-30 UA UAA200602259A patent/UA83243C2/ru unknown
- 2004-07-30 HU HUE14194507A patent/HUE037320T2/hu unknown
- 2004-07-30 TW TW093122859A patent/TWI365190B/zh active
- 2004-07-30 RS RS20060079A patent/RS53365B/sr unknown
- 2004-07-30 CA CA002534024A patent/CA2534024C/en active Active
- 2004-07-30 EP EP17173376.9A patent/EP3251679B1/en active Active
- 2004-07-30 ES ES14194507T patent/ES2649737T5/es active Active
- 2004-07-30 PL PL04771314T patent/PL1651658T5/pl unknown
- 2004-07-30 NZ NZ545304A patent/NZ545304A/en unknown
- 2004-07-30 EP EP12176099.5A patent/EP2514756B1/en active Active
- 2004-07-30 DK DK04771314.4T patent/DK1651658T4/da active
- 2004-07-30 SG SG200805626-9A patent/SG145694A1/en unknown
- 2004-07-30 PL PL14194507.1T patent/PL2896397T5/pl unknown
- 2004-07-30 ES ES17173376T patent/ES2844401T3/es active Active
- 2004-07-30 SI SI200432417T patent/SI2896397T2/sl unknown
- 2004-07-30 CN CNA2004800220078A patent/CN1829729A/zh active Pending
- 2004-07-30 EA EA200800924A patent/EA015104B1/ru not_active IP Right Cessation
- 2004-07-30 MY MYPI20043105A patent/MY143203A/en unknown
- 2004-07-30 ES ES04771314T patent/ES2402098T5/es active Active
- 2004-07-30 PT PT47713144T patent/PT1651658E/pt unknown
- 2004-07-30 CN CN201310090402.0A patent/CN103214471B/zh active Active
- 2004-07-30 DK DK14194507.1T patent/DK2896397T4/da active
- 2004-07-30 BR BRPI0413232A patent/BRPI0413232B8/pt active IP Right Grant
-
2005
- 2005-01-31 US US11/045,446 patent/US7943788B2/en active Active
-
2006
- 2006-01-10 IL IL173050A patent/IL173050A/en active Protection Beyond IP Right Term
- 2006-01-13 CR CR8188A patent/CR8188A/es unknown
- 2006-01-16 NO NO20060220A patent/NO333933B1/no unknown
- 2006-02-27 ZA ZA200601685A patent/ZA200601685B/xx unknown
- 2006-05-15 ZA ZA200603879A patent/ZA200603879B/xx unknown
- 2006-05-15 ZA ZA200603881A patent/ZA200603881B/xx unknown
- 2006-05-15 ZA ZA200603882A patent/ZA200603882B/xx unknown
- 2006-07-31 HK HK06108470.6A patent/HK1086277A1/xx active IP Right Maintenance
-
2007
- 2007-01-01 ZA ZA200700550A patent/ZA200700550B/en unknown
-
2008
- 2008-04-08 JP JP2008100074A patent/JP5065135B2/ja not_active Expired - Fee Related
-
2010
- 2010-02-10 CR CR11263A patent/CR11263A/es not_active IP Right Cessation
- 2010-07-06 IL IL206831A patent/IL206831A/en not_active IP Right Cessation
-
2011
- 2011-01-13 US US13/005,757 patent/US8202984B2/en active Active
- 2011-07-01 US US13/174,814 patent/US8222219B2/en active Active
-
2012
- 2012-05-18 NO NO20120585A patent/NO334706B1/no not_active IP Right Cessation
-
2013
- 2013-02-12 HR HRP20130124TT patent/HRP20130124T4/hr unknown
- 2013-03-14 CY CY20131100223T patent/CY1113813T1/el unknown
-
2014
- 2014-04-09 HU HUS1400021C patent/HUS1400021I1/hu unknown
- 2014-04-09 LU LU92426C patent/LU92426I2/fr unknown
- 2014-04-18 FR FR14C0034C patent/FR14C0034I2/fr active Active
- 2014-04-24 CY CY2014016C patent/CY2014016I1/el unknown
- 2014-04-25 NO NO2014009C patent/NO2014009I2/no not_active Application Discontinuation
- 2014-04-29 BE BE2014C027C patent/BE2014C027I2/nl unknown
- 2014-05-14 NL NL300670C patent/NL300670I2/nl unknown
-
2017
- 2017-11-24 HR HRP20171838TT patent/HRP20171838T4/hr unknown
- 2017-12-06 CY CY20171101284T patent/CY1119814T1/el unknown
